Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.70 |
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | LTA4H | P09960 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.70 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL6175053 | 0.98 | ALDH1A1 (0.68) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL1771825 | 0.93 | ALDH1A1 (0.79) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL23610361 | 0.91 | ALDH1A1 (0.83) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL11152023 | 0.84 | RAB9A (0.58) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL15829173 | 0.83 | ALDH1A1 (0.66) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL430121 | 0.83 | LTA4H (0.83) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL128793 | 0.83 | ALDH1A1 (1.00) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL5321407 | 0.83 | LTA4H (1.00) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL428793 | 0.83 | RAB9A (0.96) | ALDH1A1RAB9ANPC1MAPTLTA4H | |
| SCHEMBL231094 | 0.83 | LTA4H (0.80) | ALDH1A1RAB9ANPC1MAPTLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60197681-A | — | — | None | — | — | JP | disclosed |
| EP-3528324-B1 | COATED LITHIUM-NICKEL COMPOSITE OXIDE PARTICLES AND METHOD FOR PRODUCING COATED LITHIUM-NICKEL COMPOSITE OXIDE PARTICLES | SUMITOMO METAL MINING CO (JP) | 2021-11-17 | — | — | EP | disclosed |
| EP-3159956-B1 | COVERED LITHIUM-NICKEL COMPOSITE OXIDE PARTICLES, AND METHOD FOR MANUFACTURING COVERED LITHIUM-NICKEL COMPOSITE OXIDE PARTICLES | SUMITOMO METAL MINING CO (JP) | 2021-11-03 | — | — | EP | disclosed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| CN-106463722-B | Coated lithium-nickel composite oxide particle and method for producing coated lithium-nickel composite oxide particle | 住友金属矿山株式会社 | 2020-10-02 | — | — | CN | disclosed |
| US-10749182-B2 | Coated lithium-nickel composite oxide particles and method for producing coated lithium-nickel composite oxide particles | SUMITOMO METAL MINING CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| CN-106663803-B | Coated lithium-nickel composite oxide particle and method for producing coated lithium-nickel composite oxide particle | 住友金属矿山株式会社 | 2020-05-22 | — | — | CN | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10553860-B2 | Covered lithium-nickel composite oxide particles, and method for manufacturing covered lithium-nickel composite oxide particles | SUMITOMO METAL MINING CO., LTD. (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-0871619-B1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMA (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6458959-B1 | VIRICIDES AND ENZYME INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6348477-B1 | SUBSTITUTED PHENYL THIAZOLE DERIVATIVES AS VIRICIDES | BOEHRINGER INGELHEIM(CANADA) LTD. (CA) | 2002-02-19 | — | — | US | disclosed |
| US-6288091-B1 | COMPOUNDS SUCH AS 2,2,2-TRICHLOROETHYL N-(4-(2-AMINO-4-THIAZOLYL)-PHENYL)CARBAMATE THAT INHIBIT THE HERPES HELCASE-PRIMASE ENZYME COMPLEX | BOEHRINGER INGELHEIM LTD. (CA) | 2001-09-11 | — | — | US | disclosed |
| US-6057451-A | AMINOTHIAZOLE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6043254-A | ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-28 | — | — | US | disclosed |
| CN-1207094-A | Phenyl thiazole derivatives with anti herpes virus properties | BOEHRINGER INGELHEIM PHARMA (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0871619-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024343-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| JP-S60197681-A | PYRIDINE DERIVATIVE OR ITS SALT | MITSUBISHI CHEM IND LTD | 1985-10-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | ALDH1A1 2397/4885RAB9A 458/4885NPC1 1451/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | ALDH1A1 607/4885RAB9A 554/4885NPC1 333/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | ALDH1A1 647/4885RAB9A 1811/4885NPC1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.